Intellia Therapeutics, Inc. (NTLA:NASDAQ) closed at $11.42 on October 16, 2026, up 0.71% on the day. The stock trades 59.6% below its 52-week high of $28.25 and 43.6% above its 52-week low of $7.95. Over the past year, it lost 53.9%. Intellia Therapeutics, Inc. is part of the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -9.22% | -6.85% | +4.58% | -24.92% | -53.86% |
In 252 trading sessions since October 16, 2025, NTLA closed higher on 123 days (49%). Its best day was June 15, 2026 (+23.20%) and its worst was October 27, 2025 (-42.23%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 2 times.
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Find more stocks like NTLA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.